Skip to main content

Advertisement

Log in

Pharmacotherapy of heart failure in the elderly: adverse events

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Aging is associated with numerous alterations in body composition and organ function that result in substantial changes in the absorption, distribution, metabolism, and elimination of virtually all drugs. In addition, older patients with heart failure (HF) almost invariably have multiple coexisting medical conditions for which they are receiving medications. This article reviews common adverse drug effects and drug interactions associated with HF therapy in older patients and discusses strategies for reducing the risk of adverse drug events. In order to minimize these risks, it is essential that clinicians avoid prescribing unnecessary medications, adjust medication dosages to optimally balance benefits and side effects, and remain ever vigilant to the potential for medications to cause or contribute to clinically important adverse events and impaired quality of life. In treating older HF patients, the oft-cited dictum “start low, go slow” clearly applies. Despite the inherent challenges, with careful management and close follow-up, most older HF patients can be successfully treated through the judicious use of guideline-recommended HF therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Stegemann S, Ecker F, Maio M et al (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev 9:384–398

    Article  PubMed  Google Scholar 

  2. Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76

    Article  PubMed  CAS  Google Scholar 

  3. Braunstein JB, Anderson GF, Gerstenblith G et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233

    Article  PubMed  Google Scholar 

  4. Rich MW (2005) Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Card 14:134–141

    Article  Google Scholar 

  5. Stevens LA, Levey AS (2005) Chronic kidney disease in the elderly—how to assess risk. N Engl J Med 352:2122–2124

    Article  PubMed  CAS  Google Scholar 

  6. Hanlon JT, Aspinall SL, Semla TP et al (2009) Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 57:335–340

    Article  PubMed  Google Scholar 

  7. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG (2008) The aging kidney. Kidney Internat 74(6):710–720

    Article  CAS  Google Scholar 

  8. Kenney WL, Chiu P (2001) Influence of age on thirst and fluid intake. Med Sci Sports Exerc 33:1524–1532

    Article  PubMed  CAS  Google Scholar 

  9. Shem S (1979) House of God. Random House, Inc, New York

    Google Scholar 

  10. Steinman MA, Hanlon JT (2010) Managing medications in clinically complex elders. “There’s got to be a happy medium”. JAMA 304:1592–1601

    Article  PubMed  CAS  Google Scholar 

  11. Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752

    Article  PubMed  CAS  Google Scholar 

  12. Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587

    Article  PubMed  CAS  Google Scholar 

  13. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    Article  PubMed  CAS  Google Scholar 

  14. Levey AS, Bosch JP, Lewis JB (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new predication equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470

    PubMed  CAS  Google Scholar 

  15. Massie BM, Armtrong PW, Cleland JG et al (2001) Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 161:165–171

    Article  PubMed  CAS  Google Scholar 

  16. Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312–2318

    PubMed  CAS  Google Scholar 

  17. Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551

    Article  PubMed  CAS  Google Scholar 

  18. Tamirisa KP, Aaronson KD, Koelling TM (2004) Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148:971–978

    Article  PubMed  CAS  Google Scholar 

  19. Braunstein GD (2007) Clinical practice. Gynecomastia. N Engl J Med 357:1229–1237

    Article  PubMed  CAS  Google Scholar 

  20. Hunt SA, Abraham WT, Chin MH et al (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation 119:e391–e479

    Article  PubMed  Google Scholar 

  21. Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107:346–354

    Article  PubMed  Google Scholar 

  22. Lakatta EG (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 107:490–497

    Article  PubMed  Google Scholar 

  23. Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Ageing 17:353–362

    Article  CAS  Google Scholar 

  24. Ahmed A, Rich MW, Love TE et al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27:178–186

    Article  PubMed  CAS  Google Scholar 

  25. Rich MW, McSherry F, Williford WO, Yusuf S (2001) Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 38:806–813

    Article  PubMed  CAS  Google Scholar 

  26. Weil J, Sen Gupta R, Herfarth H (2004) Nonocclusive mesenteric ischemia induced by digitalis. Int J Colorectal Dis 19:277–280

    Article  PubMed  Google Scholar 

  27. Schaefer DC, Cheskin LJ (1998) Constipation in the elderly. Am Fam Phys 58:907–914

    CAS  Google Scholar 

  28. Kitzman DW, Gardin JM, Gottdiener JS et al (2001) Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 87:413–419

    Article  PubMed  CAS  Google Scholar 

  29. Heart Failure Society of America (2010) Comprehensive heart failure practice guidelines. Heart failure in patients with preserved ejection fraction. J Cardiac Fail 16:e73–e97

    Article  Google Scholar 

  30. Tsang TS, Gersh BJ, Appleton CP et al (2002) Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40:1636–1644

    Article  PubMed  Google Scholar 

  31. Seymour RM, Routledge PA (1998) Important drug–drug interactions in the elderly. Drugs Ageing 12:485–494

    Article  CAS  Google Scholar 

  32. Whelton A (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106:13S–24S

    Article  PubMed  CAS  Google Scholar 

  33. Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Int Med 160:777–784

    Article  CAS  Google Scholar 

  34. Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:1312–1322

    Article  PubMed  CAS  Google Scholar 

  35. Shirolkar SC, Fiuzat M, Becker RC (2010) Dronedarone and vitamin K antagonists: a review of drug–drug interactions. Am Heart J 160:577–582

    Article  PubMed  CAS  Google Scholar 

  36. Obialo CI, Ofili EO, Mirza T (2002) Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 90:663–665

    Article  PubMed  CAS  Google Scholar 

  37. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–2878

    Article  PubMed  CAS  Google Scholar 

  38. Cohen PA, Ernst E (2010) Safety of herbal supplements: a guide for cardiologists. Cardiovasc Therapeut 28:246–253

    Article  Google Scholar 

  39. Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A (2011) Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Cardiac Fail 17:217–223

    Article  Google Scholar 

  40. Fulmer TT, Feldman PH, Kim TS et al (1999) An intervention study to enhance medication compliance in community-dwelling elderly individuals. J Gerontol Nursing 25:6–14

    CAS  Google Scholar 

  41. Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part 1: aging arteries: a “set up” for vascular disease. Circulation 107:139–146

    Article  PubMed  Google Scholar 

  42. Gupta V, Lipsitz LA (2007) Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 120:841–847

    Article  PubMed  Google Scholar 

  43. Poluri A, Mores J, Cook DB, Findley TW, Cristian A (2005) Fatigue in the elderly population. Phys Med Rehab Clin North Am 16:91–108

    Article  Google Scholar 

  44. Wick JY, LaFleur J (2007) Fatigue: implications for the elderly. Consult Pharm 22:566–578

    Article  PubMed  Google Scholar 

  45. Choi JY, Morris JC, Hsu CY (1998) Aging and cerebrovascular disease. Neurol Clin 16:687–711

    Article  PubMed  CAS  Google Scholar 

  46. Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U (2007) Hypertension and cognitive function in the elderly. Am J Therapeut 14:533–554

    Article  Google Scholar 

Download references

Conflict of interest

Sanofi-Aventis—consultant; speaker’s bureau, Astellas Pharma US—small project grant.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael W. Rich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rich, M.W. Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev 17, 589–595 (2012). https://doi.org/10.1007/s10741-011-9263-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-011-9263-1

Keywords

Navigation